Larimar Therapeutics Inc (LRMR) Institutional Ownership & 13F Filings (Q2 2026)

LRMR ranks #3496 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

163 institutions disclose a position in LRMR, but none treat it as a major bet — even Blue Owl Capital Holdings LP, its most concentrated holder, allocates just 4.2% of its own portfolio to it.

Cliff Asness has added to its LRMR position for two straight quarters, increasing it by $5.3M to reach $7.2M today.

Israel Englander has trimmed its LRMR position for two straight quarters, cutting it by $15.8M while still holding $4.1M.

LRMR is down 1.8% today, but institutions show net buying of $43.8M this quarter — a divergence between today's price move and the underlying institutional flow.

LRMR reported a net loss of $172.6M over the trailing twelve months.

• Not yet profitable — net loss of $172.6M over the trailing twelve months
• Net income declined year over year, from -$99.8M to -$172.6M
• Operating cash flow was negative, using $113.2M in cash
• Current ratio of 2.19x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.87x equity — within a conventional range